Kate-lynn Gaylord, | |
19 Turner Rd, Moretown, VT 05660-9775 | |
(802) 279-9878 | |
Not Available |
Full Name | Kate-lynn Gaylord |
---|---|
Gender | Female |
Speciality | Occupational Therapist - Pediatrics |
Location | 19 Turner Rd, Moretown, Vermont |
Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
Identifier | Type | State | Issuer |
---|---|---|---|
1174246797 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
225X00000X | Occupational Therapist | 072.0122946 (Vermont) | Secondary |
225XP0200X | Occupational Therapist - Pediatrics | 072.0122946 (Vermont) | Primary |
Mailing Address | Practice Location Address |
---|---|
Kate-lynn Gaylord, 19 Turner Rd, Moretown, VT 05660-9775 Ph: (802) 279-9878 | Kate-lynn Gaylord, 19 Turner Rd, Moretown, VT 05660-9775 Ph: (802) 279-9878 |
News Archive
Infor-Med Corporation, makers of Praxis Electronic Medical Records (EMR), announced today the beta release of Praxis Version 5 featuring Datum, a tool that allows physicians to use free text to create, store, and share discrete clinical data.
Africa has the highest death rates in the world among critically ill COVID-19 patients, with limited intensive care resources a major factor, a study says.
A new e-book published by The Gerontological Society of America provides a primary resource for detailed overviews of the aging process across multiple organisms - from microbes to humans. This seminal publication, "Molecular and Cellular Biology of Aging," is intended as a textbook for emerging scholars of all levels.
Nearly 100 million women worldwide use birth control pills. Pills now in use contain much lower concentrations of estrogens than older preparations. The relationship between oral contraceptives and stroke has been studied and debated for decades, and studies have yielded conflicting results.
Amylin Pharmaceuticals, Inc., Eli Lilly and Company and Alkermes, Inc. today announced positive results from a phase 2 study evaluating the effects of a once-monthly injectable suspension formulation of exenatide on glycemic control in patients with type 2 diabetes.
› Verified 8 days ago